MHRA's 2026 Devices Reform: What Changes and When

Great Britain's medical device framework has been running on the Medical Devices Regulations 2002 for over two decades, propped up by CE marking extensions and transitional patches while everyone waited for the real replacement. That wait moved a significant step closer to over on May 8, 2026, when the MHRA published the draft Medical Devices (Amendment) Regulations 2026, the standalone GB regulatory framework meant to finally replace the 2002 regime.

This is not a minor update. It is the main reform of the GB device framework, and it closely realigns GB requirements with the EU MDR and IVDR, adapted for the UK market, alongside the broader IMDRF framework.

The timeline, as it actually stands

The draft regulations were notified to the World Trade Organisation for international comment, with WTO members given until July 7, 2026 to respond. In parallel, the MHRA ran its own stakeholder impact survey, open until June 19, 2026, gathering evidence on the practical cost and implementation impact of the proposals to feed into the formal impact assessment.

From here, adoption is anticipated in December 2026, with the regulations expected to enter into force around June 2027, subject to UK Parliamentary review and approval. Manufacturers get transitional runway once that happens: three years for general medical devices, five years for in vitro diagnostics (IVDs). A separate international reliance pathway, allowing faster access for devices already approved in other major jurisdictions, is expected to follow roughly 18 months after the regulations are made, putting it in the 2028 window.

What the reform actually touches

The draft regulations introduce a broad package of pre-market requirements across general medical devices, active implantable devices, and IVDs placed on the GB market. Notable elements include updated UK Essential Requirements aligned with the EU's General Safety and Performance Requirements, mandatory UDI and implant card provisions, tighter technical documentation and post-market surveillance retention rules, a Predetermined Change Control Plan pathway for software (including cybersecurity considerations), and expanded use of electronic instructions for use.

One gap is worth flagging directly for software and AI/ML teams: provisions specific to software medical devices have not been updated in this draft, reportedly pending the findings of the National AI Commission expected in summer 2026. If your product is a SaMD or AI-enabled device, the core pre-market package here applies to you, but the AI-specific detail you are likely most interested in is still coming, not finalized in this release.

Why generic UK content will not cut it here

Existing MHRA or UKCA guidance that predates May 2026 was written for a framework that this reform is actively replacing. A manufacturer relying on general UKCA marking content from a year ago is working from a picture of GB regulation that this draft already supersedes in substance, even before it is formally adopted.

This is also a genuinely multi-track compliance problem, not a single deadline to diarize. GB is moving on its own timeline while the EU MDR and IVDR continue evolving in parallel, and the two are only "closely aligned," not identical. A team tracking GB requirements in one document and EU requirements in another, manually, is one missed cross-reference away from a technical file gap it will not find until a notified body or the MHRA finds it first. That is precisely the kind of drift that continuous, cross-framework gap analysis is built to catch as each side moves.

What to check now

1. If you place devices on the GB market, review your technical documentation against the draft's updated Essential Requirements now, rather than waiting for December 2026 adoption to start.
2. Confirm whether your device qualifies for the eventual international reliance pathway, since that could materially shorten your GB market access timeline once it takes effect.
3. If you have a software or AI/ML device, do not assume silence on software provisions means no obligations are coming. Watch for the National AI Commission's findings this summer, since that will likely shape the update this draft is missing.

For foundational context on the current UK regime, see Qualio's what you should know about UKCA marking and the ultimate guide to placing a medical device on the UK market. For the regulatory detail behind this reform, see Latham & Watkins' analysis of the draft amendment and the British Healthcare Trades Association's summary of the timeline.

If you are tracking GB and EU requirements in separate systems, see how continuous gap analysis keeps multi-framework technical files aligned as each regulator moves independently.